Table 1

Comparative analysis of all pSpA* patients regarding HLA-B27 status

	HLA-B27+ (N=283)		HLA-B27− (N=507)		Univariate analysis		Multivariable analyisis
	N/mean	%/SD	N/mean	%/SD	OR	P value	OR	P value
Men	165	58.3	236	46.5	1.61 (1.20–2.16)	0.002	1.48 (1.03–2.14)	0.039
Family history	99	33.2	163	66.8	1.14 (0.83–1.54)	0.418
Age (year)	42.8	13.9	50.6	13.7	0.96 (0.95–0.97)	<0.001		n.s.*
Age onset (year)	30.7	13.0	34.7	14.7	0.98 (0.97–0.99)	<0.001	0.97 (0.96–0.99)	<0.001
Age at diagnosis (year)	35.1	13.8	43.8	13.5	0.95 (0.94–0.96)	<0.001		n.s.
Diagnostic delay (month)	4.5	7.5	9.2	11.1	0.94 (0.92–0.96)	<0.001	0.95 (0.93–0.97)	<0.001
Disease duration (year)	12.2	10.7	15.9	12.5	0.97 (0.96–0.98)	<0.001		n.s.
Psoriatic arthritis	86	30.4	388	76.5	0.13 (0.10–0.18)	<0.001	0.36 (0.19–0.68)	0.002
Mono/oligoarticular pattern	120/265	45.3	232/451	51.4	0.78 (0.58–1.06)	0.112
Tarsitis	47	16.6	52	10.3	1.74 (1.14–2.66)	0.010	1.74 (1.05–2.89)	0.033
Enthesitis	157	55.4	240	47.3	1.39 (1.04–1.86)	0.029		n.s.
Dactylitis	72	25.4	169	33.3	0.68 (0.49–0.94)	0.021		n.s.
Peripheral structural damage	28	9.9	135	26.6	0.31 (0.19–0.46)	<0.001		n.s.
Axial involvement	183	64.7	179	35.3	3.35 (2.48–4.56)	<0.001	2.49 (1.73–3.59)	<0.001
Radiographic sacroilitis (AS* mNY* criteria fulfilment)	102/261	39.1	94/460	20.4	2.50 (1.79–3.50)	<0.001		n.s.
Shoulder involvement	67	23.7	78	15.4	1.71 (1.18–2.46)	0.004		n.s.
Hip involvement	104	36.7	77	15.2	3.24 (2.31–4.58)	<0.001		n.s.
Psoriasis	92	32.5	395	77.9	0.14 (0.10–0.19)	<0.001	0.48 (0.26–0.92)	0.025
Uveitis	61	21.6	14	2.8	9.68 (5.45–18.34)	<0.001	5.78 (2.97–12.0)	<0.001
If uveitis, no of episodes	7.5	9.4	2.1	1.5	1.24 (1.00–1.75)	0.104
IBD	4	1.4	14	2.8	0.50 (0.14–1.42)	0.232
Fibromyalgia	17	6.0	62	12.2	0.46 (0.26–0.78)	0.006		n.s.

AS, ankylosing spondylitis; IBD, inflammatory bowel disease; mNY, New York modified; n.s., not significant; pSpA, peripheral spondyloarthritis.